



(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 25/28 (2006.01)
A61K 31/713 (2006.01) A61P 21/00 (2006.01)
A61P 3/06 (2006.01)

(21) International Application Number:

PCT/EP2022/060238

(22) International Filing Date:

19 April 2022 (19.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/176,814 19 April 2021 (19.04.2021) US
21186366.7 19 July 2021 (19.07.2021) EP
21213711.1 10 December 2021 (10.12.2021) EP

(71) Applicants: **NOVO NORDISK A/S** [DK/DK]; Novo Allé, 2880 Bagsværd (DK). **DICERNA PHARMACEUTICALS, INC.** [US/US]; 75 Hayden Avenue, Lexington, Massachusetts 02421 (US).

(72) Inventors: **SAXENA, Utsav**; 75 Hayden Avenue, Lexington, MA02421 (US). **DUDEK, Henryk**; 75 Hayden

Avenue, Lexington, MA02421 (US). **PURSELL, Natalie, Wayne**; 75 Hayden Avenue, Lexington, MA02421 (US). **SPIEGELMAN, Nicole, Alexis**; 75 Hayden Avenue, Lexington, MA02421 (US). **LATTA, Markus, Robert**; NOVO NORDISK A/S, Novo Allé, 2880 Bagsværd (DK). **ANDERSEN, Birgitte**; NOVO NORDISK A/S, Novo Allé, 2880 Bagsværd (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION




FIG. 1B

(57) Abstract: Oligonucleotides are provided herein that inhibit *NR1H3* expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with *NR1H3* expression.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

01 December 2022 (01.12.2022)